Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

MLA

Scher, H. I., et al. “Development and Validation of Circulating Tumour Cell Enumeration (Epic Sciences) as a Prognostic Biomarker in Men with Metastatic Castration-Resistant Prostate Cancer.” European Journal of Cancer (Oxford, England : 1990), vol. 150, June 2021, pp. 83–94. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.02.042.

APA

Scher, H. I., Armstrong, A. J., Schonhoft, J. D., Gill, A., Zhao, J. L., Barnett, E., Carbone, E., Lu, J., Antonarakis, E. S., Luo, J., Tagawa, S., Dos Anjos, C. H., Yang, Q., George, D., Szmulewitz, R., Danila, D. C., Wenstrup, R., Gonen, M., & Halabi, S. (2021). Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990), 150, 83–94. https://doi.org/10.1016/j.ejca.2021.02.042

Chicago

Scher, H I, A J Armstrong, J D Schonhoft, A Gill, J L Zhao, E Barnett, E Carbone, et al. 2021. “Development and Validation of Circulating Tumour Cell Enumeration (Epic Sciences) as a Prognostic Biomarker in Men with Metastatic Castration-Resistant Prostate Cancer.” European Journal of Cancer (Oxford, England : 1990) 150 (June): 83–94. doi:10.1016/j.ejca.2021.02.042.